U.S. REITS Stock News

Manchester United plc has reported fiscal second-quarter 2026 results, with sales of £190.31 million and a net income of £4.18 million, marking a return to profit despite lower revenue than the same period a year ago. The earnings improvement stems largely from cost and headcount reductions that turned a prior-period loss into a profit, while management reiterated full-year revenue guidance of £640 million to £660 million. We’ll now look at how this cost-driven profitability turnaround,...

Stock performance snapshot and recent context Onto Innovation (ONTO) has drawn attention after a period of strong multi year total returns and a recent share price of $215.89, prompting investors to reassess how its current valuation lines up with its fundamentals. See our latest analysis for Onto Innovation. While Onto Innovation’s share price has eased slightly in the very short term, with a 1 day share price return of a 0.91% decline, the 90 day share price return of 46.86% and 1 year...

On February 25, 2026, RXO, Inc. launched its Middle Mile Solutions service, offering a single “dock-to-door” logistics network that links first-, middle-, and last-mile transportation with value-added services such as warehousing, kitting, assembly, and reverse logistics, all managed through its RXO Connect platform for end-to-end visibility. This move expands RXO beyond pure brokerage into an integrated, tech-enabled supply chain offering that could deepen customer relationships and expand...

Why Chart Industries’ latest earnings matter for shareholders Chart Industries (GTLS) just released fourth quarter and full year 2025 results, with both net income and sales below the prior year and revenue and earnings missing Wall Street forecasts. See our latest analysis for Chart Industries. At a share price of $207.30, Chart Industries has seen relatively steady recent trading, with a 90 day share price return of 1.60% and a 1 year total shareholder return of 8.79%. This suggests that...

Analysts have recently raised their earnings estimates for InnovAge Holding (INNV) for both the current quarter and full year. This shift in expectations appears to be a key catalyst for the stock. See our latest analysis for InnovAge Holding. The recent upward revisions to earnings expectations come after a sharp run in the shares, with a 30 day share price return of 61.44% and a 1 year total shareholder return of 175.69%. This suggests momentum has recently picked up despite a weaker 5 year...

Credicorp (BAP) has put corporate governance in focus after its Board approved a refreshed slate of directors and amended its dividend policy, giving investors new context for how future cash returns may be evaluated. See our latest analysis for Credicorp. Those governance changes land after a strong run, with a 90 day share price return of 35.86% and a 1 year total shareholder return of 99.92%. However, near term share price momentum has cooled slightly around the current US$346.38 level. If...

Kimbell Royalty Partners (KRP) is back on investors’ radar after reporting fourth quarter 2025 results that included record proved developed reserves, a swing to profitability, and a higher cash distribution to unitholders. See our latest analysis for Kimbell Royalty Partners. The latest results and higher cash distribution come after a strong run in the units, with a 30 day share price return of 6.78% and a 90 day share price return of 13.72%. The 5 year total shareholder return of 126.14%...

CNX Resources (CNX) has closed a private placement of US$500 million in 5.875% senior notes due 2034. The company is using the funds to repurchase and redeem higher coupon debt maturing in 2029. See our latest analysis for CNX Resources. The recent refinancing activity comes during a period of firm share price momentum, with a 1-day share price return of 5.27%, a year-to-date share price return of 14.59%, and a 1-year total shareholder return of 44.57% helping extend a strong multi year...

Recently, Banc of California has faced renewed regional banking sector pressure as investors reacted to rising credit risk concerns and broader inflation-related worries affecting loan quality perceptions. At the same time, the bank’s merger with PacWest, ongoing loan sales, and sizeable stock repurchases highlight an active reshaping of its balance sheet and capital priorities. We’ll now examine how heightened sector-wide credit risk concerns influence Banc of California’s existing...

For investors considering whether Ralph Lauren at around US$362 a share still offers value, or if most of the opportunity is already priced in, this article walks through the key numbers so you can judge for yourself. The stock has been volatile recently, with a 5.8% decline over the last 7 days, a 2.6% gain over the past month, and a 35.4% return over the last year, in addition to a very large 3 year gain and a 228.3% 5 year return. Alongside these moves, investors have been weighing...

Worthington Enterprises (WOR) has drawn investor attention after recent share performance data highlighted mixed short term moves alongside stronger longer term returns, prompting a closer look at how its Consumer and Building Products segments are contributing. See our latest analysis for Worthington Enterprises. Recent trading has cooled slightly, with a 1 day share price return of 2.08% and a 7 day share price return of 2.01%. At the same time, a 1 year total shareholder return of 35.18%...

If you are wondering whether Spectrum Brands Holdings is still attractively priced or already reflecting its potential, you are in the right place for a clear, valuation focused look at the stock. The share price recently closed at US$78.38, with returns of 23.0% over 30 days and 30.5% year to date, while the 1 year return sits at 4.4% and the 3 and 5 year returns are 28.8% and 8.8% respectively. This naturally raises questions about how much value is already priced in. Recent news around...

Protagonist Therapeutics recently reported a US$44.38 million fourth‑quarter net loss and a full‑year 2025 net loss of US$130.15 million, reversing from profits a year earlier. At the same time, the company advanced its pipeline by submitting an NDA for rusfertide and outlining plans to change its profit‑sharing arrangement with Takeda, signaling a potential shift in how it may capture future economics from this program. With shares rising over the past week, we'll explore how the rusfertide...

Avista (AVA) just posted its full year 2025 results, reporting higher earnings, a 24th consecutive annual dividend increase to US$1.97 per share, and updated guidance along with regulatory and project developments that drew investor attention. See our latest analysis for Avista. At a share price of US$40.62, Avista has seen a 1 day share price return of 2.14% and a year to date share price return of 4.91%. Its 1 year total shareholder return of 6.78% and 5 year total shareholder return of...

Burford Capital (BUR) just reported its Q4 and full-year 2025 results, showing much lower revenue and profitability than a year earlier, and also declared a final dividend that may interest income focused investors. See our latest analysis for Burford Capital. That earnings miss and softer full year profitability appear to be weighing on sentiment. A 7 day share price return of 12.54% and a 30 day share price return of 12.63% have contributed to a 1 year total shareholder return of 45.28%,...

Why Mercury General’s latest earnings matter for investors Mercury General (MCY) just posted fourth quarter and full year 2025 results with higher revenue and net income year over year, alongside a reaffirmed quarterly dividend. This gives investors fresh data on profitability and cash returns. See our latest analysis for Mercury General. Mercury General’s latest results and dividend affirmation have come alongside a 7 day share price return of 4.79% and a softer 90 day share price return of...

Xenon Pharmaceuticals (XENE) is back in focus after reporting wider fourth quarter and full year 2025 losses, followed by a US$400 million at the market follow on equity offering in its common shares. See our latest analysis for Xenon Pharmaceuticals. The US$43.23 share price has seen a mixed stretch, with a 5.41% 1 month share price return and a 2.37% 7 day gain, but a modest year to date decline and recent pressure following the wider losses and US$400 million at the market offering...

Taylor Morrison Home (TMHC) is back in focus after two years of order backlog declines averaging 33.6% year over year and analyst forecasts indicating a 17.2% revenue drop over the coming year. See our latest analysis for Taylor Morrison Home. The share price has held around US$65.89 with a 30 day share price return of 8.11% and a 12.00% year to date share price return. The 5 year total shareholder return of 143.14% highlights how much of the story sits in longer holding periods as current...

Southwest Gas Holdings reported past full-year 2025 results with revenue of US$1,940.38 million and net income of US$439.83 million, while also announcing a 4% increase in its quarterly dividend to US$0.645 per share starting in the second quarter of 2026. Alongside these financial moves, the company completed its shift to a fully regulated natural gas utility and outlined sizeable capital investments and regulatory initiatives that could reshape its earnings profile and shareholder payout...

In February 2026, BKV Corporation reported fourth-quarter 2025 results showing revenue rising to US$330.09 million and net income of US$70.38 million, marking a shift from a loss a year earlier alongside higher natural gas production. The company also advanced its integrated gas, power and carbon capture model, including a US$500 million carbon capture partnership and refreshed CCUS injection targets that deepen its low-carbon energy ambitions. We’ll now explore how BKV’s move to...

Tuya (TUYA) is in focus ahead of its March 2, 2026 quarterly earnings release, as investors watch to see whether the company can meet expectations for $0.03 in earnings per share and provide guidance that supports its outlook. See our latest analysis for Tuya. At a share price of $2.55, Tuya has seen strong near term momentum, with a 1 day share price return of 5.37% and a 30 day share price return of 22.01%. However, its 1 year total shareholder return of 22.17% and 3 year total shareholder...

In recent days, Centessa Pharmaceuticals reported positive Phase 2a progress for its lead orexin receptor agonist ORX750 in narcolepsy and idiopathic hypersomnia, alongside updates on its broader neurology and neuropsychiatry pipeline. This progress, combined with broad analyst support despite the absence of approved products, is sharpening attention on Centessa’s orexin-focused early-stage portfolio and upcoming clinical and regulatory milestones. We’ll now examine how the encouraging...

Veracyte, Inc. recently reported its fourth-quarter and full-year 2025 results, with revenue rising to US$140.64 million in Q4 and US$517.15 million for the year, alongside a jump in net income to US$41.15 million for the quarter and US$66.35 million for 2025. The company reaffirmed its 2026 revenue guidance of US$570 million to US$582 million and highlighted two upcoming cancer diagnostics launches, TRUE MRD for bladder cancer and Prosigna for early-stage breast cancer, as key growth...

Valmont Industries recently approved a 13% increase in its quarterly cash dividend to US$0.77 per share, lifting the annualized payout to US$3.08 and scheduled for payment on April 15, 2026, while also appointing agribusiness executive Paul Maass to its now eleven-member Board of Directors. This combination of a higher cash return and the addition of a director with deep global agriculture and supply chain experience highlights Valmont’s emphasis on aligning capital allocation with sector...